

Author: Lehman Emily J.H.
Publisher: Oxford University Press
ISSN: 1460-2083
Source: Human Molecular Genetics, Vol.12, Iss.22, 2003-11, pp. : 2949-2956
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Alzheimer's disease (AD) is a multigenic neurodegenerative disorder characterized by distinct neuropathological hallmarks including deposits of the -amyloid (A) peptide. A is a 39- to 43-amino acid peptide derived from the proteolytic processing of the amyloid precursor protein (APP). While increasing evidence suggests that altered APP processing and A metabolism is a common feature of AD, the relationship between the levels of A and various APP products and the onset of AD remains unclear. We have undertaken a screen to characterize genetic factors that modify APP processing, A metabolism and A deposition in a genomic-based yeast artificial chromosome (YAC) transgenic mouse model of AD. A mutant human APP YAC transgene was transferred to three inbred mouse strains. Despite similar levels of holo-APP expression in the congenic strains, the levels of APP C-terminal fragments as well as brain and plasma A in young animals varied by genetic background. Furthermore, we demonstrate that age-dependent A deposition in the APP YAC transgenic model is dramatically altered depending on the congenic strain examined. These studies demonstrate that APP processing, A metabolism and A deposition are regulated by genetic background and that analysis of these phenotypes in mice should provide new insights into the factors that regulate AD pathogenesis.
Related content




A reporter for amyloid precursor protein -secretase activity in Drosophila
By Guo Ming
Human Molecular Genetics, Vol. 12, Iss. 20, 2003-10 ,pp. :


By Chapuis Julien Vingtdeux Valérie Campagne Fabien Davies Peter Marambaud Philippe
Human Molecular Genetics, Vol. 20, Iss. 10, 2011-05 ,pp. :

